JYB1907 in Subjects With Advanced Solid Tumors

Summary

A Phase I, Multi-center, Open-label Study with Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects with Advanced Solid Tumors

Timeline

Start

2023-07-31

Primary completion

2024-09-15

Completion

2024-10-31

Drugs

Indications